Lupron Depot prostate cancer

Recommended dosage and monitoring requirements According to Micromedex, the effective doses of Lupron in prostate cancer are 1 mg subcutaneously daily, or in the depot formulation 7.5 mg intramuscularly (IM) monthly, 11.25 mg every 3 months, or 30 mg every 4 months. Lupron Depot-3 month 22.5 mg is used in the treatment of advanced prostate cancer. In endometriosis, the effective dose is 3.75mg depot IM monthly or 11.25mg every 3 months for 6 months. In central precocious puberty, the recommended starting dose of Lupron Injection Pediatric is 50pg/kg... [Pg.235]

N. Agarwal, D. Fletcher, and J. Ward, Obesity and Treatment of Prostate Cancer What is the right dose of Lupron Depot , Clinical Cancer Research An Official Journal of the American Association of Cancer Research, Vol. 13 (13), p. 4027,2007. [Pg.182]

B. Indications and use Lupron Injection, Lupron Depot, Lupron Depot-3 Month, and Lupron Depot-4 Month are indicated in the palliative treatment of advanced prostate cancer. These products offer an alternative treatment when orchiectomy or estrogen administration is either not indicated or unacceptable to the patient. Lupron Injection Pediatric and Lupron Depot-PED are indicated in the treatment of children with central precocious puberty. Lupron Depot and Lupron Depot-3 Month are indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions. [Pg.234]

Lupron Depot PLA Leuprolide acetate Prostate cancer, endometreosis... [Pg.349]

Based on these limitations, only a limited number of drug delivery systems based on biodegradable polymers have so far been successfully commercialized. One example is Lupron Depot one-month injectable microspheres of PLGA containing leuprorelin acetate (LH-RH agonist) for the treatment of endometriosis and prostatic cancer [31,32]. [Pg.70]

The Lupron Depot microspheres are indicated for the treatment of male patients with prostate cancer and female patients suffering from endometriosis and anemia due to fibroids. Each depot formulation is... [Pg.92]

Lupron Depot Leuprolide PLGA or PLA TAP Prostate cancer, endometriosis... [Pg.396]

Leuprolide (Lupron, Lupron Depot, Eligard)S Prostate cancer breast cancer... [Pg.2314]

Leuprolide acetate, a synthetic nonapeptide, is prescribed for the treatment of metastatic prostate cancer and endometriosis. Leuprolide acetate is presented in a number of injectable dosage forms including Lupron sterile solution for subcutaneous administration (1 and 5 mg mL 1) and Lupron depot controlled release formulation for intramuscular injection (3.75 and 7.5 mg). Zheng and Fulu [106] have evaluated the in vivo effect of leuprolide loaded micro emulsions on the genital organs of the male and female rats. In the preliminary pharmacokinetic studies, oral microemulsions of leuprolide administration resulted in 10-fold higher plasma levels of leuprolide as compared to that of saline solution (Fig. 9.4). [Pg.280]

LUPRON DEPOT Drug-delivery device for prostate cancer... [Pg.5]

Okada and co-workers (1988,1989,1991) and Ogawa etal. (1988) have also described a 75 25 PLGA microencapsulated 30-day release system for the delivery of another LHRH analog leuproUde acetate [(D-Leu , Pro NEt)-LHRH Lupron Depot , Takeda-Abbott], Their results indicate that a single injection of microcapsules maintains constant and effective serum levels of the analog for one month. Sufficient therapeutic efficacy in the treatment of advanced prostatic cancer has also been shown for leuprolide acetate, and the product has recently been approved for use by the U.S. Food and Drug Administration (Lupron Depot , 7.5mg PDR, 1994). This treatment has also shown to cause a dramatic regression of... [Pg.53]

The biggest success of pol5mier controlled release systems in cancer therapy however has been in the area of prostate cancer treatment. This therapy is luiique since it uses a hormone-suppressant rather than a chemotherapeutic agent to minimize cancer cell growth in the prostate. Several products include Lupron Depot (TAP Pharmaceuticals), Zoladex (Astra-Zeneca), and Trelstar Depot (Debio RP, Pharmacia). Lupron Depot involves PLA microspheres, Zoladex formulation is an extruded rod, whereas Trelstar depot consists of PLGA microspheres, all of which incorporate LHRH analogues. [Pg.1870]

Lupron Depot Leuprolide acetate TAP Prostate cancer Marketed... [Pg.157]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...